glycine has been researched along with Dermatitis Medicamentosa in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 9.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, S | 1 |
| Moreau, P | 1 |
| Hari, P | 1 |
| Mateos, MV | 1 |
| Ludwig, H | 1 |
| Shustik, C | 1 |
| Masszi, T | 1 |
| Spencer, A | 1 |
| Hájek, R | 1 |
| Romeril, K | 1 |
| Avivi, I | 1 |
| Liberati, AM | 1 |
| Minnema, MC | 1 |
| Einsele, H | 1 |
| Lonial, S | 1 |
| Berg, D | 1 |
| Lin, J | 1 |
| Gupta, N | 1 |
| Esseltine, DL | 1 |
| Richardson, PG | 1 |
| Kurokawa, I | 1 |
| Umehara, M | 1 |
| Hashimoto, A | 1 |
| Hozu, S | 1 |
| Romano, A | 2 |
| Pietrantonio, F | 1 |
| di Fonso, M | 2 |
| Pocobelli, D | 1 |
| Venuti, A | 2 |
| Mormile, F | 1 |
| Quaratino, D | 1 |
| Giuffreda, F | 1 |
1 trial available for glycine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
3 other studies available for glycine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Vesicular drug eruption due to stronger Neo-Minophagen C.
Topics: Aged; Cysteine; Drug Combinations; Drug Eruptions; Glycine; Glycyrrhizic Acid; Humans; Injections, I | 2005 |
Delayed hypersensitivity to stepronin: a case report.
Topics: Aerosols; Aged; Bronchial Provocation Tests; Drug Eruptions; Expectorants; Facial Dermatoses; Female | 1993 |
Accelerated cell-mediated broncho-obstructive reaction to inhaled stepronin: a case report.
Topics: Administration, Inhalation; Adult; Bronchial Spasm; Drug Eruptions; Expectorants; Glycine; Humans; H | 1996 |